Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5976_Библиотеки_им_академика_М_И_Перельмана
.pdf
points for optimization into novel health products like medicines, cosmetics and food supple-
ments. However, there are still some barriers to overcome mainly due to some issues such as
its accessibility and sustainable supply and regulatory limitations.
This review provides a broad overview of natural-based health products and representa-
tive contributions to human health. To enlarge and establish the usefulness of natural prod-
ucts, it is now mandatory to focus on identification of unused plants, to find new sources of
bioactives. Once this new lead molecule is obtained, it should be fully characterized. For a
drug, this can be used for further exploration through QSAR studies, molecular modeling,
and in vivo studies followed by clinical trials (phase 1e4). But when a novel drug comes
out with success, intellectual property rights can be a hurdle task, since naturally occurring
compounds in their original form may not easily be patented. Besides, in this point, the legal
frameworks of these products vary between countries and this fact can limit the process.
Another key challenge is that scientific and technological expertises are often scattered
over many companies and academic institutions. Thus, focused efforts are needed to better
support this translation. A possible solution to improve it could be to focus the relevant
expertise under one umbrella and in close spatial proximity. But this only happens because
the humanity is gifted with nature, and human being is skilled with brain; so let us make use
of it.
References
[1] Sundar Dhilip Kumar S, Houreld N, Abrahamse H. Therapeutic potential and recent advances of curcumin in
the treatment of aging-associated diseases. Molecules 2018;23(4):835.
[2] Lichota A, Gwozdzinski K. Anticancer activity of natural compounds from plant and marine environment. In-
ternational Journal of Molecular Sciences 2018;19(11):3533.
[3] Springob K, Kutchan TM. Introduction to the different classes of natural products. Plant-derived natural prod-
ucts. New York, NY: Springer US; 2009. p. 3e50.
[4] Khan H. Therapeutic potential of alkaloids in cough treatment. Biology and Medicine 2015;08(02).
[5] Lu J-J, Bao J-L, Chen X-P, Huang M, Wang Y-T. Alkaloids isolated from natural herbs as the anticancer agents.
Evidence-Based Complementary and Alternative Medicine 2012;2012:1e12.
[6] Kurek J. Introductory chapter: alkaloids - their importance in nature and for human life. IntechOpen; 2019.
[7] Neelam KA, Sharma KK. Phenylpropanoids and its derivatives: biological activities and its role in food, phar-
maceutical and cosmetic industries. Critical Reviews in Food Science and Nutrition 2020;60(16):2655e75.
[8] Vogt T. Phenylpropanoid biosynthesis. Molecular Plant 2010;3(1):2e20.
[9] Jucá MM, Cysne Filho FMS, de Almeida JC, Mesquita D da S, Barriga JR de M, Dias KCF, et al. Flavonoids:
biological activities and therapeutic potential. Natural Product Research 2020;34(5):692e705.
[10] Panche AN, Diwan AD, Chandra SR. Flavonoids: an overview. Journal of Nutrition Sciences 2016;5:e47.
[11] Brodowska K. Natural flavonoids: classification, potential role, and application of flavonoid analogues. Euro-
pean Journal of Biological Research 2017;7:108e23.
[12] Miyanaga A. Structure and function of polyketide biosynthetic enzymes: various strategies for production of
structurally diverse polyketides. Bioscience Biotechnology & Biochemistry 2017;81(12):2227e36.
[13] Risdian C, Mozef T, Wink J. Biosynthesis of polyketides in streptomyces. Microorganisms 2019;7(5):124.
[14] Gomes ES, Schuch V, Lemos EGDM. Biotechnology of polyketides: new breath of life for the novel antibiotic
genetic pathways discovery through metagenomics. Brazilian Journal of Microbiology 2013;44(4):1007e34.
[15] Gupta P. Polyketides of therapeutic significance from natural sources. Journal of Traditional Medicine and
Clinical Naturopathy 2016;05(03).
[16] Lacoske MH, Theodorakis EA. Spirotetronate polyketides as leads in drug discovery. Journal of Natural Prod-
ucts 2015;78(3):562e75.
[17] Perveen S. Introductory chapter: terpenes and terpenoids. Terpenes and terpenoids. IntechOpen; 2018.
3. Challenges in delivery of plant actives68
https://t.me/med1917
[18] Wang G, Tang W, Bidigare RR. Terpenoids as therapeutic drugs and pharmaceutical agents. Natural Products.
Totowa, NJ: Humana Press; 2005. p. 197e227.
[19] Pichersky E, Raguso RA. Why do plants produce so many terpenoid compounds? New Phytologist
2018;220(3):692e702.
[20] Chin Y-T, Cheng G-Y, Shih Y-J, Lin C-Y, Lin S-J, Lai H-Y, et al. Therapeutic applications of resveratrol and its
derivatives on periodontitis. Annals of the New York Academy of Sciences 2017;1403(1):101e8.
[21] Arora D, Jaglan S. Therapeutic applications of resveratrol nanoformulations. Environmental Chemistry Letters
2018;16(1):35e41.
[22] Salehi B, Del Prado-Audelo ML, Cortés H, Leyva-Gómez G, Stojanovi
c-Radi
c Z, Singh YD, et al. Therapeutic
applications of curcumin nanomedicine formulations in cardiovascular diseases. Journal of Clinical Medicine
2020;9(3):746.
[23] Stohs SJ, Chen O, Ray SD, Ji J, Bucci LR, Preuss HG. Highly bioavailable forms of curcumin and promising
avenues for curcumin-based research and application: a review. Molecules 2020;25(6):1397.
[24] Mota AH, Andrade JM, Rodrigues MJ, Custódio L, Bronze MR, Duarte N, et al. Synchronous insight of in vitro
and in vivo biological activities of Sambucus nigra L. extracts for industrial uses. Industrial Crops and Products
2020;154:112709.
[25] Sridevi Sangeetha KS, Umamaheswari S, Uma Maheswara Reddy C, Narayana Kalkura S. Flavonoids: thera-
peutic potential of natural pharmacological agents. International Journal of Pharmaceutical Sciences and
Research 2016;7(10):3924e30.
[26] Feng S-L, Tian Y, Huo S, Qu B, Liu R-M, Xu P, et al. Nobiletin potentiates paclitaxel anticancer efficacy in
A549/T xenograft model: pharmacokinetic and pharmacological study. Phytomedicine 2020;67:153141.
[27] Salehi B, Venditti A, Sharifi-Rad M, Kregiel D, Sharifi-Rad J, Durazzo A, et al. The therapeutic potential of api-
genin. International Journal of Molecular Sciences 2019;20(6):1305.
[28] Lin Y, Shi R, Wang X, Shen H-M. Luteolin, a flavonoid with potential for cancer prevention and therapy. Cur-
rent Cancer Drug Targets 2008;8(7):634e46.
[29] Montané X, Kowalczyk O, Reig-Vano B, Bajek A, Roszkowski K, Tomczyk R, et al. Current perspectives of the
applications of polyphenols and flavonoids in cancer therapy. Molecules 2020;25(15):3342.
[30] Mrudulakumari Vasudevan U, Lee EY. Flavonoids, terpenoids, and polyketide antibiotics: role of glycosylation
and biocatalytic tactics in engineering glycosylation. Biotechnology Advances 2020;41:107550.
[31] Bergman ME, Davis B, Phillips MA. Medically useful plant terpenoids: biosynthesis, occurrence, and mecha-
nism of action. Molecules 2019;24(21):3961.
[32] Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and
chemopreventive agents. Medical Principles and Practice 2016;25(2):41e59.
[33] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646e74.
[34] Braicu C, Mehterov N, Vladimirov B, Sarafian V, Nabavi SM, Atanasov AG, et al. Nutrigenomics in cancer:
revisiting the effects of natural compounds. Seminars in Cancer Biology 2017;46:84e106.
[35] Majolo F, de Oliveira Becker Delwing LK, Marmitt DJ, Bustamante-Filho IC, Goettert MI. Medicinal plants and
bioactive natural compounds for cancer treatment: important advances for drug discovery. Phytochemistry
Letters 2019;31:196e207.
[36] Dong Z, Zhang D, Yang R, Wang S. Paclitaxel: new uses for an old drug. Drug Design, Development and Ther-
apy 2014;8:279.
[37] Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, et al. Natural compounds for cancer treatment and
prevention. Pharmacological Research 2009;59(6):365e78.
[38] Bracher F, Tremmel T. From lead to drug utilizing a mannich reaction: the topotecan story. Archiv der Phar-
mazie 2017;350(7):e1600236.
[39] Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacological Research 2019;148:104398.
[40] Martino E, Della Volpe S, Terribile E, Benetti E, Sakaj M, Centamore A, et al. The long story of camptothecin:
from traditional medicine to drugs. Bioorganic & Medicinal Chemistry Letters 2017;27(4):701e7.
[41] Oberlies NH, Kroll DJ. Camptothecin and taxol: historic achievements in natural products research. Journal of
Natural Products 2004;67(2):129e35.
[42] Rohr JR, Barrett CB, Civitello DJ, Craft ME, Delius B, DeLeo GA, et al. Emerging human infectious diseases and
the links to global food production. Nature Sustainability 2019;2(6):445e56.
References 69
https://t.me/med1917
[43] Waldvogel FA. Infectious diseases in the 21st century: old challenges and new opportunities. International
Journal of Infectious Diseases 2004;8(1):5e12.
[44] Dadgostar P. Antimicrobial resistance: implications and costs. Infection and Drug Resistance 2019;12:3903e10.
[45] Hemaiswarya S, Kruthiventi AK, Doble M. Synergism between natural products and antibiotics against infec-
tious diseases. Phytomedicine 2008;15(8):639e52.
[46] Bloom DE, Black S, Salisbury D, Rappuoli R. Antimicrobial resistance and the role of vaccines. Proceedings of
the National Academy of Sciences 2018;115(51):12868e71.
[47] Salam AM, Quave CL. Opportunities for plant natural products in infection control. Current Opinion in Micro-
biology 2018;45:189e94.
[48] Ahmad Khan MS, Ahmad I. Herbal medicine. New look to phytomedicine. Elsevier; 2019. p. 3e13.
[49] Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Current Opinion in Microbi-
ology 2019;51:72e80.
[50] Wright GD. Opportunities for natural products in 21st century antibiotic discovery. Natural Product Reports
2017;34(7):694e701.
[51] Rossiter SE, Fletcher MH, Wuest WM. Natural products as platforms to overcome antibiotic resistance. Chem-
ical Reviews 2017;117(19):12415e74.
[52] Khameneh B, Iranshahy M, Soheili V, Fazly Bazzaz BS. Review on plant antimicrobials: a mechanistic view-
point. Antimicrobial Resistance and Infection Control 2019;8(1):118.
[53] Cushnie TPT, Cushnie B, Lamb AJ. Alkaloids: an overview of their antibacterial, antibiotic-enhancing and anti-
virulence activities. International Journal of Antimicrobial Agents 2014;44(5):377e86.
[54] Savoia D. Plant-derived antimicrobial compounds: alternatives to antibiotics. Future Microbiology
2012;7(8):979e90.
[55] Zakaryan H, Arabyan E, Oo A, Zandi K. Flavonoids: promising natural compounds against viral infections.
Archives of Virology 2017;162(9):2539e51.
[56] Ahmad A, Kaleem M, Ahmed Z, Shafiq H. Therapeutic potential of flavonoids and their mechanism of action
against microbial and viral infectionsda review. Food Research International 2015;77:221e35.
[57] Ludwiczuk A, Skalicka-Wo
zniak K, Georgiev MI. Terpenoids. Pharmacognosy. Elsevier; 2017. p. 233e66.
[58] Zacchino SA, Butassi E, Di Liberto M, Raimondi M, Postigo A, Sortino M. Plant phenolics and terpenoids as
adjuvants of antibacterial and antifungal drugs. Phytomedicine 2017;37:27e48.
[59] Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated
diseases in organs. Oncotarget 2018;9(6):7204e18.
[60] Fürst R, Zündorf I. Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the
translation of preclinical knowledge into clinical progress. Mediators of Inflammation 2014;2014:1e9.
[61] Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the eti-
ology of disease across the life span. Nature Medicine 2019;25(12):1822e32.
[62] Krishnamoorthy S, Honn KV. Inflammation and disease progression. Cancer Metastasis Rev 2006;25(3):481e91.
[63] Sychrová A, Koláriková I,
Zemli
cka M,
Smejkal K. Natural compounds with dual antimicrobial and anti-
inflammatory effects. Phytochemistry Reviews 2020;19(6):1471e502.
[64] Maleki SJ, Crespo JF, Cabanillas B. Anti-inflammatory effects of flavonoids. Food Chemistry 2019;299:125124.
[65] Choy KW, Murugan D, Leong X-F, Abas R, Alias A, Mustafa MR. Flavonoids as natural anti-inflammatory
agents targeting nuclear factor-kappa B (NFkB) signaling in cardiovascular diseases: a mini review. Frontiers
in Pharmacology 2019;10:1295.
[66] Souto AL, Tavares JF, da Silva MS, Diniz MDFFM, de Athayde-Filho PF, Barbosa Filho JM. Anti-inflammatory
activity of alkaloids: an update from 2000 to 2010. Molecules 2011;16(10):8515e34.
[67] José Serrano Vega R, Campos Xolalpa N, Josabad Alonso Castro A, Pérez González C, Pérez Ramos J, Pérez
Gutiérrez S. Terpenes from natural products with potential anti-inflammatory activity. Terpenes and terpe-
noids. IntechOpen; 2018.
[68] Heras B, Hortelano S. Molecular basis of the anti-inflammatory effects of terpenoids. Inflammation and Allergy
- Drug Targets 2009;8(1):28e39.
[69] Korkina L, Kostyuk V, De Luca C, Pastore S. Plant phenylpropanoids as emerging anti-inflammatory agents.
Mini-Reviews in Medicinal Chemistry 2011;11(10):823e35.
[70] de Cássia da Silveira e Sá R, Andrade L, dos Reis Barreto de Oliveira R, de Sousa D. A review on anti-
inflammatory activity of phenylpropanoids found in essential oils. Molecules 2014;19(2):1459e80.
3. Challenges in delivery of plant actives70
https://t.me/med1917
[71] Calixto JB. The role of natural products in modern drug discovery. Anais da Academia Brasileira de Ciencias
2019;91(Suppl. 3).
[72] Patridge E, Gareiss P, Kinch MS, Hoyer D. An analysis of FDA-approved drugs: natural products and their
derivatives. Drug Discovery Today 2016;21(2):204e7.
[73] Jamshidi-Kia F, Lorigooini Z, Amini-Khoei H. Medicinal plants: past history and future perspective. Journal of
Herbmed Pharmacology 2018;7(1):1e7.
[74] Patra JK, Das G, Lee S, Kang S-S, Shin H-S. Selected commercial plants: a review of extraction and isolation of
bioactive compounds and their pharmacological market value. Trends in Food Science and Technology
2018;82:89e109.
[75] McChesney JD, Venkataraman SK, Henri JT. Plant natural products: back to the future or into extinction?
Phytochemistry 2007;68(14):2015e22.
[76] Atanasov AG, Waltenberger B, Pferschy-Wenzig E-M, Linder T, Wawrosch C, Uhrin P, et al. Discovery and
resupply of pharmacologically active plant-derived natural products: a review. Biotechnology Advances
2015;33(8):1582e614.
[77] Howat S, Park B, Oh IS, Jin Y-W, Lee E-K, Loake GJ. Paclitaxel: biosynthesis, production and future prospects.
New Biotechnology 2014;31(3):242e5.
[78] Yun B-W, Yan Z, Amir R, Hong S, Jin Y-W, Lee E-K, et al. Plant natural products: history, limitations and the
potential of cambial meristematic cells. Biotechnology & Genetic Engineering Reviews 2012;28(1):47e60.
[79] Veeresham C. Natural products derived from plants as a source of drugs. Journal of Advanced Pharmaceutical
Technology & Research 2012;3(4):200.
[80] Mushtaq S, Abbasi BH, Uzair B, Abbasi R. Natural products as reservoirs of novel therapeutic agents. EXCLI
Journal 2018;17:420e51.
[81] Süntar I. Importance of ethnopharmacological studies in drug discovery: role of medicinal plants. Phytochem-
istry Reviews 2020;19(5):1199e209.
[82] Appendino G, Minassi A, Taglialatela-Scafati O. Recreational drug discovery: natural products as lead struc-
tures for the synthesis of smart drugs. Natural Product Reports 2014;31(7):880.
[83] Brower V. Back to nature: extinction of medicinal plants threatens drug discovery. JNCI Journal of the National
Cancer Institute 2008;100(12):838e9.
[84] Minh CV, Nhiem NX, Yen HT, Kiem PV, Tai BH, Le Tuan Anh H, et al. Chemical constituents of Trichosanthes
kirilowii and their cytotoxic activities. Archives of Pharmacal Research 2015;38(8):1443e8.
[85] Lahlou M. The success of natural products in drug discovery. Pharmacology & Pharmacy 2013;04(03):17e31.
[86] Ahn K. The worldwide trend of using botanical drugs and strategies for developing global drugs. BMB Reports
2017;50(3):111e6.
[87] Wright GD. Unlocking the potential of natural products in drug discovery. Microbial Biotechnology
2019;12(1):55e7.
[88] Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and oppor-
tunities. Nature Reviews Drug Discovery 2021;20:200e16.
[89] Bernardini S, Tiezzi A, Laghezza Masci V, Ovidi E. Natural products for human health: an historical overview
of the drug discovery approaches. Natural Product Research 2018;32(16):1926e50.
[90] Pan S-Y, Zhou S-F, Gao S-H, Yu Z-L, Zhang S-F, Tang M-K, et al. New perspectives on how to discover drugs
from herbal medicines: CAM’s outstanding contribution to modern therapeutics. Evidence-Based Complemen-
tary and Alternative Medicine 2013;2013:1e25.
[91] FDA. FDA-approved drugs 2020.
[92] Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. Journal
of Natural Products 2012;75(3):311e35.
[93] Coimbra M, Isacchi B, van Bloois L, Torano JS, Ket A, Wu X, et al. Improving solubility and chemical stability of
natural compounds for medicinal use by incorporation into liposomes. International Journal of Pharmaceutics
2011;416(2):433e42.
[94] Ramalho MJ, Andrade S, Loureiro JA, do Carmo Pereira M. Nanotechnology to improve the Alzheimer’s dis-
ease therapy with natural compounds. Drug Delivery and Translational Research 2020;10(2):380e402.
[95] Watkins R, Wu L, Zhang C, Davis R, Xu B. Natural product-based nanomedicine: recent advances and issues.
International Journal of Nanomedicine 2015;10:6055.
References 71
https://t.me/med1917
[96] Bilia AR, Piazzini V, Asprea M, Risaliti L, Vanti G, Bergonzi MC. Plants extracts loaded in nanocarriers: an
emergent formulating approach. Natural Product Communications 2018;13(9):1157e60.
[97] Teleszko M, Wojdyło A, Rudzi
nska M, Oszmia
nski J, Golis T. Analysis of lipophilic and hydrophilic bioactive
compounds content in sea buckthorn (hippophaë rhamnoides L.) berries. Journal of Agricultural and Food
Chemistry 2015;63(16):4120e9.
[98] Kyriakoudi A, Spanidi E, Mourtzinos I, Gardikis K. Innovative delivery systems loaded with plant bioactive
ingredients: formulation approaches and applications. Plants 2021;10(6):1238.
[99] Girish BP, Dariya B, Mannarapu M, Nagaraju GP, Raju GSR. Targeting the tumor microenvironment of pancre-
atic ductal adenocarcinoma using nano-phytomedicines. Seminars in cancer biology. 2021.
[100] Elmowafy M, Samy A, Raslan MA, Salama A, Said RA, Abdelaziz AE, et al. Enhancement of bioavailability and
pharmacodynamic effects of thymoquinone via nanostructured lipid carrier (NLC) formulation. AAPS PharmS-
ciTech 2016;17(3):663e72.
[101] Rahat I, Imam SS, Rizwanullah M, Alshehri S, Asif M, Kala C, et al. Thymoquinone-entrapped chitosan-
modified nanoparticles: formulation optimization to preclinical bioavailability assessments. Drug Delivery
2021;28(1):973e84.
[102] Bhia M, Motallebi M, Abadi B, Zarepour A, Pereira-Silva M, Saremnejad F, et al. Naringenin nano-delivery sys-
tems and their therapeutic applications. Pharmaceutics 2021;13(2):291.
[103] Paolino D, Cosco D, Cilurzo F, Fresta M. Innovative drug delivery systems for the administration of natural
compounds. Current Bioactive Compounds 2007;3(4):262e77.
[104] Rahman HS, Othman HH, Hammadi NI, Yeap SK, Amin KM, Abdul Samad N, et al. Novel drug delivery sys-
tems for loading of natural plant extracts and their biomedical applications. International Journal of Nanome-
dicine 2020;15:2439e83.
[105] Nagpal M, Goyal A, Kumar S, Singh I, Arora S. Potential of novel drug delivery systems for herbal drugs. In-
dian Journal of Pharmaceutical Education and Research 2011;45:225e35.
[106] Sandhiya V, Ubaidulla U. A review on herbal drug loaded into pharmaceutical carrier techniques and its eval-
uation process. Future Journal of Pharmaceutical Sciences 2020;6(1):51.
[107] Afrin S, Jahan I, Hasan A, Deepa K. Novel approaches of herbal drug delivery. Journal of Pharmaceutical
Research International 2018;21(5):1e11.
[108] Sarangi M, Padhi S. Novel herbal drug delivery system: an overview. Archives of Medicine and Health Sci-
ences 2018;6(1):171.
[109] Shinde N, Aloorkar N, Kulkarni A. Recent advances in vesicular drug delivery system. Research Journal of
Pharmaceutical Dosage Forms and Technology 2014;6:975e4377.
[110] Amaral M, Pereiro AB, Gaspar MM, Reis CP. Recent advances in ionic liquids and nanotechnology for drug
delivery. Nanomedicine 2021;16(1):63e80.
[111] Obeid MA, Al Qaraghuli MM, Alsaadi M, Alzahrani AR, Niwasabutra K, Ferro VA. Delivering natural prod-
ucts and biotherapeutics to improve drug efficacy. Therapeutic Delivery 2017;8(11):947e56.
[112] Jain N, Valli K, Devi V. Importance of novel drug delivery systems in herbal medicines. Pharmacognosy Re-
views 2010;4(7):27.
[113] Jain S, Jain V, Mahajan SC. Lipid based vesicular drug delivery systems. Advances in Pharmacy
2014;2014:1e12.
[114] Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Frontiers of
Chemistry 2018;6:630.
[115] Saxena SK, Nyodu R, Kumar S, Maurya VK. Current advances in nanotechnology and medicine. NanoBioMe-
dicine. Singapore: Springer Singapore; 2020. p. 3e16.
[116] Mota AH, Sousa A, Figueira M, Amaral M, Sousa B, Rocha J, et al. Natural-based consumer health nanoprod-
ucts: medicines, cosmetics, and food supplements. Handbook of functionalized nanomaterials for industrial ap-
plications. Elsevier; 2020. p. 527e78.
[117] Martins JP, das Neves J, de la Fuente M, Celia C, Florindo H, Günday-Türeli N, et al. The solid progress of
nanomedicine. Drug Delivery and Translational Research 2020;10(3):726e9.
[118] Vishnu P, Roy V. Clinical experience with nanoparticle albumin bound (nab) paclitaxel (AbraxaneÒ). 2014.
p. 541e56.
[119] Canal F, Sanchis J, Vicent MJ. Polymeredrug conjugates as nano-sized medicines. Current Opinion in Biotech-
nology 2011;22(6):894e900.
3. Challenges in delivery of plant actives72
https://t.me/med1917
[120] Giodini L, Lo RF, Campagnol D, Marangon E, Posocco B, Dreussi E, et al. Nanocarriers in cancer clinical prac-
tice: a pharmacokinetic issue. Nanomedicine: Nanotechnology, Biology and Medicine 2017;13(2):583e99.
[121] Narvekar M, Xue HY, Eoh JY, Wong HL. Nanocarrier for poorly water-soluble anticancer drugsdbarriers of
translation and solutions. AAPS PharmSciTech 2014;15(4):822e33.
[122] Rivankar S. An overview of doxorubicin formulations in cancer therapy. Journal of Cancer Research and Ther-
apeutics 2014;10(4):853.
[123] Forssen EA, Ross ME. DaunoxomeÒ treatment of solid tumors: preclinical and clinical investigations. Journal
of Liposome Research 1994;4(1):481e512.
[124] Harrison TS, Lyseng-Williamson KA. Vincristine sulfate liposome injection. BioDrugs 2013;27(1):69e74.
[125] Zhang H. Onivyde for the therapy of multiple solid tumors. OncoTargets and Therapy 2016:3001.
[126] Hartrick CT, Hartrick KA. Extended-release epidural morphine (DepoDur
TM
): review and safety analysis.
Expert Review of Neurotherapeutics 2008;8(11):1641e8.
[127] Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly
soluble actives. International Journal of Pharmaceutics 2010;399(1e2):129e39.
[128] Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities.
Nature Reviews Cancer 2017;17(1):20e37.
[129] Silva P, Bonifácio B, Ramos M, Negri K, Maria Bauab T, Chorilli M. Nanotechnology-based drug delivery sys-
tems and herbal medicines: a review. International Journal of Nanomedicine 2013;9:1.
[130] Zorzi GK, Carvalho ELS, von Poser GL, Teixeira HF. On the use of nanotechnology-based strategies for asso-
ciation of complex matrices from plant extracts. Revista Brasileira de Farmacognosia 2015;25(4):426e36.
[131] Rout GK, Shin H-S, Gouda S, Sahoo S, Das G, Fraceto LF, et al. Current advances in nanocarriers for biomedical
research and their applications. Artificial Cells, Nanomedicine, and Biotechnology 2018;46(Suppl. 2):1053e62.
[132] Ananikov VP. Organiceinorganic hybrid nanomaterials. Nanomaterials 2019;9(9):1197.
[133] Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharmaceutical
Journal 2018;26(1):64e70.
[134] Colone M, Calcabrini A, Stringaro A. Drug delivery systems of natural products in oncology. Molecules
2020;25(19):4560.
[135] Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug delivery: is the enhanced permeability and
retention effect sufficient for curing cancer? Bioconjugate Chemistry 2016;27(10):2225e38.
[136] Golombek SK, May J-N, Theek B, Appold L, Drude N, Kiessling F, et al. Tumor targeting via EPR: strategies to
enhance patient responses. Advanced Drug Delivery Reviews 2018;130:17e38.
[137] Kalyane D, Raval N, Maheshwari R, Tambe V, Kalia K, Tekade RK. Employment of enhanced permeability and
retention effect (EPR): nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in
cancer. Materials Science and Engineering: C 2019;98:1252e76.
[138] Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug
Metabolism and Personalized Therapy 2019;34(1).
[139] Li R, Zheng K, Yuan C, Chen Z, Huang M. Be active or not: the relative contribution of active and passive tu-
mor targeting of nanomaterials. Nanotheranostics 2017;1(4):346e57.
[140] Behera A, Padhi S. Passive and active targeting strategies for the delivery of the camptothecin anticancer drug:
a review. Environmental Chemistry Letters 2020;18(5):1557e67.
[141] Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer
therapeutics. Nature Communications 2018;9(1):1410.
[142] Pearce AK, O’Reilly RK. Insights into active targeting of nanoparticles in drug delivery: advances in clinical
studies and design considerations for cancer nanomedicine. Bioconjugate Chemistry 2019;30(9):2300e11.
[143] Kumar Khanna V. Targeted delivery of nanomedicines. ISRN Pharmacology 2012;2012:571394.
[144] Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug
delivery systems. Cancers 2019;11(5):640.
[145] Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies
to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol 2019;71(8):1185e98.
[146] Muro S. Challenges in design and characterization of ligand-targeted drug delivery systems. Journal of
Controlled Release 2012;164(2):125e37.
[147] Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Molec-
ular Membrane Biology 2010;27(7):286e98.
References 73
https://t.me/med1917
[148] Al-Jamal KT. Active drug targeting: lessons learned and new things to consider. International Journal of Phar-
maceutics 2013;454(1):525e6.
[149] Salvioni L, Rizzuto MA, Bertolini JA, Pandolfi L, Colombo M, Prosperi D. Thirty years of cancer nanomedicine:
success, frustration, and hope. Cancers 2019;11(12):1855.
[150] Girija AR. Medical applications of polymer/functionalized nanoparticle systems. Polymer composites with
functionalized nanoparticles. Elsevier; 2019. p. 381e404.
[151] Zieli
nska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric nanoparticles: produc-
tion, characterization, toxicology and ecotoxicology. Molecules 2020;25(16):3731.
[152] Mosaddik A, Ravinayagam V, Elaanthikkal S, Fessi H, Badri W, Elaissari A. Development and use of polymeric
nanoparticles for the encapsulation and administration of plant extracts. Natural products as source of mole-
cules with therapeutic potential. Cham: Springer International Publishing; 2018. p. 391e463.
[153] Safari J, Zarnegar Z. Advanced drug delivery systems: nanotechnology of health design A review. Journal of
Saudi Chemical Society 2014;18(2):85e99.
[154] El-Say KM, El-Sawy HS. Polymeric nanoparticles: promising platform for drug delivery. International Journal
of Pharmaceutics 2017;528(1e2):675e91.
[155] Mandal AK. Dendrimers in targeted drug delivery applications: a review of diseases and cancer. International
Journal of Polymeric Materials and Polymeric Biomaterials 2021;70(4):287e97.
[156] Pandita D, Poonia N, Kumar S, Lather V, Madaan K. Dendrimers in drug delivery and targeting: drug-
dendrimer interactions and toxicity issues. Journal of Pharmacy and BioAllied Sciences 2014;6(3):139.
[157] Patel V, Rajani C, Paul D, Borisa P, Rajpoot K, Youngren-Ortiz SR, et al. Dendrimers as novel drug-delivery
system and its applications. Drug delivery system. Elsevier; 2020. p. 333e92.
[158] Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chemical So-
ciety Reviews 2012;41(7):2545.
[159] Crucho CIC. Stimuli-responsive polymeric nanoparticles for nanomedicine. ChemMedChem 2015;10(1):24e38.
[160] Liu X, Yang Y, Urban MW. Stimuli-responsive polymeric nanoparticles. Macromolecular Rapid Communica-
tions 2017;38(13):1700030.
[161] Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA. Paclitaxel: what has been done and the
challenges remain ahead. International Journal of Pharmaceutics 2017;526(1e2):474e95.
[162] Maya S, Sabitha M, Nair SV, Jayakumar R. Phytomedicine-loaded polymeric nanomedicines: potential cancer
therapeutics. 2012. p. 203e39.
[163] Yuan H, Guo H, Luan X, He M, Li F, Burnett J, et al. Albumin nanoparticle of paclitaxel (Abraxane) decreases
while Taxol increases breast cancer stem cells in treatment of triple negative breast cancer. Molecular Pharma-
ceutics 2020;17(7):2275e86.
[164] Grigoletto A, Tedeschini T, Canato E, Pasut G. The evolution of polymer conjugation and drug targeting for the
delivery of proteins and bioactive molecules. WIREs Nanomedicine and Nanobiotechnology 2020.
[165] Barkat MA, Beg S, Pottoo FH, Ahmad FJ. Nanopaclitaxel therapy: an evidence based review on the battle for
next-generation formulation challenges. Nanomedicine 2019;14(10):1323e41.
[166] Gaspar DP, Faria V, Gonçalves LMD, Taboada P, Remuñán-López C, Almeida AJ. Rifabutin-loaded solid lipid
nanoparticles for inhaled antitubercular therapy: physicochemical and in vitro studies. International Journal of
Pharmaceutics 2017;497(1e2):199e209.
[167] Muller RH, Shegokar R, Keck CM. 20 Years of lipid nanoparticles (SLN & NLC): present state of development
& industrial applications. Current Drug Discovery Technologies 2011;8(3):207e27.
[168] Farinha P, Pinho JO, Matias M, Gaspar MM. Nanomedicines in the treatment of colon cancer: a focus on metal-
lodrugs. Drug Delivery and Translational Research 2021.
[169] Cruz MEM, Simões SI, Corvo ML, Martins MBF, Gaspar MM. Formulation of NPDDS for macromolecules. In:
Pathak Y, Thassu D, editors. Drug delivery nanoparticles formulation and characterization. New York, USA:
Informa Healthcare; 2009. p. 35e49.
[170] Bozzuto G, Molinari A. Liposomes as nanomedical devices. International Journal of Nanomedicine
2015;10:975e99.
[171] Deshpande PP, Biswas S, Torchilin VP. Current trends in the use of liposomes for tumor targeting. Nanome-
dicine 2013;8(9):1509e28.
[172] Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chemical Reviews
2015;115(19):10938e66.
3. Challenges in delivery of plant actives74
https://t.me/med1917
[173] Pinho JO, Lopes J, Albino M, Reis C, Matias M, Gaspar MM. Advances in nanotechnology-related strategies
against melanoma. In: de Oliveira MRBT, editor. Mitochondrial dysfunction and nanotherapeutics. Elsevier;
2021. p. 385e424.
[174] Wang G, Wang J-J, Wang Y-Z, Feng S, Jing G, Fu X-L. Myricetin nanoliposomes induced SIRT3-mediated
glycolytic metabolism leading to glioblastoma cell death. Artificial Cells, Nanomedicine, and Biotechnology
2018;46(Suppl. 3):S180e91.
[175] Belfiore L, Saunders DN, Ranson M, Thurecht KJ, Storm G, Vine KL. Towards clinical translation of ligand-
functionalized liposomes in targeted cancer therapy: challenges and opportunities. Journal of Controlled
Release 2018;277:1e13.
[176] Gruner BA, Weitman SD. The folate receptor as a potential therapeutic anticancer target. Investigational New
Drugs 1998;16(3):205e19.
[177] Wang C, Feng L, Yang X, Wang F, Lu W. Folic acid-conjugated liposomal vincristine for multidrug resistant
cancer therapy. Asian Journal of Pharmaceutical Sciences 2013;8(2):118e27.
[178] Sriraman SK, Salzano G, Sarisozen C, Torchilin V. Anti-cancer activity of doxorubicin-loaded liposomes co-
modified with transferrin and folic acid. European Journal of Pharmaceutics and Biopharmaceutics
2016;105:40e9.
[179] Sapra P, Allen TM. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposo-
mal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clinical Cancer Research
2004;10(7):2530e7.
[180] Du R, Zhong T, Zhang W-Q, Song P, Song W-D, Zhao Y, et al. Antitumor effect of iRGD-modified liposomes
containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma. International Journal of Nano-
medicine 2014;9:3091e105.
[181] Lee Y, Thompson DH. Stimuli-responsive liposomes for drug delivery. Wiley Interdisciplinary Reviews: Nano-
medicine Nanobiotechnology 2017;9(5):e1450.
[182] Caddeo C, Pons R, Carbone C, Fernàndez-Busquets X, Cardia MC, Maccioni AM, et al. Physico-chemical char-
acterization of succinyl chitosan-stabilized liposomes for the oral co-delivery of quercetin and resveratrol. Car-
bohydrate Polymers 2017;157:1853e61.
[183] Zarrabi A, Zarepour A, Khosravi A, Alimohammadi Z, Thakur VK. Synthesis of curcumin loaded smart pH-
responsive stealth liposome as a novel nanocarrier for cancer treatment. Fibers 2021;9(3):19.
[184] Lee S, Song SJ, Lee J, Ha TH, Choi JS. Cathepsin B-responsive liposomes for controlled anticancer drug delivery
in hep G2 cells. Pharmaceutics 2020;12(9):876.
[185] Tsai M-J, Huang Y-B, Fang J-W, Fu Y-S, Wu P-C. Preparation and characterization of naringenin-loaded elastic
liposomes for topical application. PLoS One 2015;10(7):e0131026.
[186] Fernandes M, Lopes I, Magalhães L, Sárria MP, Machado R, Sousa JC, et al. Novel concept of exosome-like li-
posomes for the treatment of Alzheimer’s disease. Journal of Controlled Release 2021;336:130e43.
[187] Silva CO, Pinho JO, Lopes JM, Almeida AJ, Gaspar MM, Reis C. Current trends in cancer nanotheranostics:
metallic, polymeric, and lipid-based systems. Pharmaceutics 2019;11(1):22.
[188] Wang M, Li L, Zhang X, Liu Y, Zhu R, Liu L, et al. Magnetic resveratrol liposomes as a new theranostic plat-
form for magnetic resonance imaging guided Parkinson’s disease targeting therapy. ACS Sustainable Chemis-
try & Engineering 2018;6(12):17124e33.
[189] Zhou H, Xia L, Zhong J, Xiong S, Yi X, Chen L, et al. Plant-derived chlorophyll derivative loaded liposomes for
tri-model imaging guided photodynamic therapy. Nanoscale 2019;11(42):19823e31.
[190] Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the
state of the art. European Journal of Pharmaceutics and Biopharmaceutics 2000;50(1):161e77.
[191] Wissing SA, Kayser O, Müller RH. Solid lipid nanoparticles for parenteral drug delivery. Advanced Drug De-
livery Reviews 2004;56(9):1257e72.
[192] Lopes RM, Gaspar MM, Pereira J, Eleutério CV, Carvalheiro M, Almeida AJ, et al. Liposomes versus lipid nano-
particles: comparative study of lipid-based systems as oryzalin carriers for the treatment of leishmaniasis. Jour-
nal of Biomedical Nanotechnology 2014;10(12):3647e57.
[193] zur Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery e drug
release and release mechanism. European Journal of Pharmaceutics and Biopharmaceutics 1998;45(2):149e55.
References 75
https://t.me/med1917
[194] Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising
drug delivery systems for future clinics. Nanomedicine: Nanotechnology, Biology and Medicine
2016;12(1):143e61.
[195] Müller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs.
International Journal of Pharmaceutics 2002;242(1e2):121e8.
[196] Cunha S, Forbes B, Sousa Lobo JM, Silva AC. Improving drug delivery for Alzheimer’s disease through nose-
to-brain delivery using nanoemulsions, nanostructured lipid carriers (NLC) and in situ hydrogels. International
Journal of Nanomedicine 2021;16:4373e90.
[197] Costa CP, Barreiro S, Moreira JN, Silva R, Almeida H, Sousa Lobo JM, et al. In vitro studies on nasal formu-
lations of nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN). Pharmaceuticals
2021;14(8):711.
[198] Bhatt R, Singh D, Prakash A, Mishra N. Development, characterization and nasal delivery of rosmarinic acid-
loaded solid lipid nanoparticles for the effective management of Huntington’s disease. Drug Delivery
2015;22(7):931e9.
[199] Wang L, Zhao X, Du J, Liu M, Feng J, Hu K. Improved brain delivery of pueraria flavones via intranasal admin-
istration of borneol-modified solid lipid nanoparticles. Nanomedicine 2019;14(16):2105e19.
[200] Maroufi NF, Vahedian V, Mazrakhondi SAM, Kooti W, Khiavy HA, Bazzaz R, et al. Sensitization of MDA-
MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-
G1 cell cycle arrest mechanism. Naunyn-Schmiedeberg’s Archives of Pharmacology 2020;393(1):1e11.
[201] Jain A, Sharma G, Kushwah V, Thakur K, Ghoshal G, Singh B, et al. Fabrication and functional attributes of
lipidic nanoconstructs of lycopene: an innovative endeavour for enhanced cytotoxicity in MCF-7 breast cancer
cells. Colloids Surfaces B Biointerfaces 2017;152:482e91.
[202] Brezaniova I, Hruby M, Kralova J, Kral V, Cernochova Z, Cernoch P, et al. Temoporfin-loaded 1-tetradecanol-
based thermoresponsive solid lipid nanoparticles for photodynamic therapy. Journal of Controlled Release
2016;241:34e44.
[203] Caldas AR, Catita J, Machado R, Ribeiro A, Cerqueira F, Horta B, et al. Omega-3- and resveratrol-loaded lipid
nanosystems for potential use as topical formulations in autoimmune, inflammatory, and cancerous skin dis-
eases. Pharmaceutics 2021;13(8):1202.
[204] Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in
cosmetic and dermatological preparations. Advanced Drug Delivery Reviews 2002;54:S131e55.
[205] López-García R, Ganem-Rondero A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC):
occlusive effect and penetration enhancement ability. Journal of Cosmetics, Dermatological Sciences and Ap-
plications 2015;05(02):62e72.
[206] Liakopoulou A, Mourelatou E, Hatziantoniou S. Exploitation of traditional healing properties, using the nano-
technology’s advantages: the case of curcumin. Toxicology Reports 2021;8:1143e55.
[207] Carbone C, Caddeo C, Grimaudo MA, Manno DE, Serra A, Musumeci T. Ferulic acid-NLC with Lavandula
essential oil: a possible strategy for wound-healing? Nanomaterials 2020;10(5):898.
[208] Zdu
nska K, Dana A, Kolodziejczak A, Rotsztejn H. Antioxidant properties of ferulic acid and its possible appli-
cation. Skin Pharmacology and Physiology 2018;31(6):332e6.
[209] Fang J-Y, Fang C-L, Liu C-H, Su Y-H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid
nanoparticles (SLN) versus nanostructured lipid carriers (NLC). European Journal of Pharmaceutics and Bio-
pharmaceutics 2008;70(2):633e40.
[210] Ren Y, Song X, Tan L, Guo C, Wang M, Liu H, et al. A review of the pharmacological properties of psoralen.
Frontiers in Pharmacology 2020;11:1406.
[211] Huang Z, Hua S, Yang Y, Fang J. Development and evaluation of lipid nanoparticles for camptothecin delivery:
a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacolog-
ica Sinica 2008;29(9):1094e102.
[212] Valcourt C, Saulnier P, Umerska A, Zanelli MP, Montagu A, Rossines E, et al. Synergistic interactions between
doxycycline and terpenic components of essential oils encapsulated within lipid nanocapsules against gram
negative bacteria. International Journal of Pharmaceutics 2016;498(1e2):23e31.
[213] Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Interna-
tional Journal of Pharmaceutics 2009;379(2):201e
9.
3. Challenges in delivery of plant actives76
https://t.me/med1917
[214] Hureaux J, Lagarce F, Gagnadoux F, Vecellio L, Clavreul A, Roger E, et al. Lipid nanocapsules: ready-to-use
nanovectors for the aerosol delivery of paclitaxel. European Journal of Pharmaceutics and Biopharmaceutics
2009;73(2):239e46.
[215] Vasconcelos AG, Valim MO, Amorim AGN, do Amaral CP, de Almeida MP, Borges TKS, et al. Cytotoxic ac-
tivity of poly-e-caprolactone lipid-core nanocapsules loaded with lycopene-rich extract from red guava (Psi-
dium guajava L.) on breast cancer cells. Food Research International 2020;136:109548.
[216] Abdelmoneem MA, Elnaggar MA, Hammady RS, Kamel SM, Helmy MW, Abdulkader MA, et al. Dual-
targeted lactoferrin shell-oily core nanocapsules for synergistic targeted/herbal therapy of hepatocellular car-
cinoma. ACS Applied Materials & Interfaces 2019;11(30):26731e44.
[217] Balzeau J, Pinier M, Berges R, Saulnier P, Benoit J-P, Eyer J. The effect of functionalizing lipid nanocapsules
with NFL-TBS.40-63 peptide on their uptake by glioblastoma cells. Biomaterials 2013;34(13):3381e9.
[218] Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. Journal of
Controlled Release 2012;163(1):34e45.
[219] Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharmaceutical Research 2006;24(1):1e16.
[220] Ma M, Hao Y, Liu N, Yin Z, Wang L, Liang X, et al. A novel lipid-based nanomicelle of docetaxel: evaluation of
antitumor activity and biodistribution. International Journal of Nanomedicine 2012;7:3389e98.
[221] Julien JA, Mutchek SG, Wittenberg NJ, Glover KJ. Biophysical characterization of full-length oleosin in dode-
cylphosphocholine micelles. Proteins: Structure, Function, and Bioinformatics 2021.
[222] Bilia AR, Bergonzi MC, Guccione C, Manconi M, Fadda AM, Sinico C. Vesicles and micelles: two versatile vec-
tors for the delivery of natural products. Journal of Drug Delivery Science and Technology 2016;32:241e55.
[223] Fernández-García R, Lalatsa A, Statts L, Bolás-Fernández F, Ballesteros MP, Serrano DR. Transferosomes as
nanocarriers for drugs across the skin: quality by design from lab to industrial scale. International Journal of
Pharmaceutics 2020;573:118817.
[224] Caddeo C, Manca ML, Peris JE, Usach I, Diez-Sales O, Matos M, et al. Tocopherol-loaded transfersomes:
in vitro antioxidant activity and efficacy in skin regeneration. International Journal of Pharmaceutics
2018;551(1e2):34e41.
[225] Sarwa KK, Mazumder B, Rudrapal M, Verma VK. Potential of capsaicin-loaded transfersomes in arthritic rats.
Drug Delivery 2015;22(5):638e46.
[226] Ramezani V, Honarvar M, Seyedabadi M, Karimollah A, Ranjbar AM, Hashemi M. Formulation and optimi-
zation of transfersome containing minoxidil and caffeine. Journal of Drug Delivery Science and Technology
2018;44:129e35.
[227] Jangdey MS, Gupta A, Saraf S, Saraf S. Development and optimization of apigenin-loaded transfersomal sys-
tem for skin cancer delivery: in vitro evaluation. Artificial Cells, Nanomedicine, and Biotechnology
2017;45(7):1452e62.
[228] Pandey V, Golhani D, Shukla R. Ethosomes: versatile vesicular carriers for efficient transdermal delivery of
therapeutic agents. Drug Delivery 2015;22(8):988e1002.
[229] Touitou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes d novel vesicular carriers for enhanced deliv-
ery: characterization and skin penetration properties. Journal of Controlled Release 2000;65(3):403e18.
[230] Yu Z, Lv H, Han G, Ma K. Ethosomes loaded with cryptotanshinone for acne treatment through topical gel
formulation. PLoS One 2016;11(7):e0159967.
[231] Lohani A, Verma A, Hema G, Pathak K. Topical delivery of Geranium/Calendula essential oil-entrapped etha-
nolic lipid vesicular cream to combat skin aging. BioMed Research International 2021;2021:1e13.
[232] Hallan SS, Sguizzato M, Mariani P, Cortesi R, Huang N, Simelière F, et al. Design and characterization of etho-
somes for transdermal delivery of caffeic acid. Pharmaceutics 2020;12(8):740.
[233] Liao B, Ying H, Yu C, Fan Z, Zhang W, Shi J, et al. ()-Epigallocatechin gallate (EGCG)-nanoethosomes as a
transdermal delivery system for docetaxel to treat implanted human melanoma cell tumors in mice. Interna-
tional Journal of Pharmaceutics 2016;512(1):22e31.
[234] Kaur CD, Saraf S. Topical vesicular formulations of Curcuma longa extract on recuperating the ultraviolet
radiation-damaged skin. Journal of Cosmetic Dermatology 2011;10(4):260e5.
[235] Choi J-H, Cho S-H, Yun J-J, Yu Y-B, Cho C-W. Ethosomes and transfersomes for topical delivery of ginsenoside
Rh1 from red ginseng: characterization and in vitro evaluation. Journal of Nanoscience and Nanotechnology
2015;15(8):5660e2.
References 77
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана